Developing Drugs for Core Social and Communication Impairment in Autism

David J. Posey, Craig A. Erickson, Christopher J. McDougle

Research output: Contribution to journalReview article

47 Citations (Scopus)

Abstract

There are many challenges to studying drug effects on core social and language impairment in autism. Drugs such as fenfluramine, naltrexone, and secretin do not appear to be efficacious for these core symptoms. Risperidone has led to improvement in some aspects of social relatedness when used to treat irritability in autism. More research is needed on the utility of selective serotonin reuptake inhibitors, cholinergic drugs, glutamatergic drugs, and oxytocin for core autistic symptoms.

Original languageEnglish (US)
Pages (from-to)787-801
Number of pages15
JournalChild and Adolescent Psychiatric Clinics of North America
Volume17
Issue number4
DOIs
StatePublished - Oct 1 2008

Fingerprint

Autistic Disorder
Communication
Pharmaceutical Preparations
Fenfluramine
Naltrexone
Secretin
Risperidone
Serotonin Uptake Inhibitors
Oxytocin
Cholinergic Agents
Language
Research

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health

Cite this

Developing Drugs for Core Social and Communication Impairment in Autism. / Posey, David J.; Erickson, Craig A.; McDougle, Christopher J.

In: Child and Adolescent Psychiatric Clinics of North America, Vol. 17, No. 4, 01.10.2008, p. 787-801.

Research output: Contribution to journalReview article

Posey, David J. ; Erickson, Craig A. ; McDougle, Christopher J. / Developing Drugs for Core Social and Communication Impairment in Autism. In: Child and Adolescent Psychiatric Clinics of North America. 2008 ; Vol. 17, No. 4. pp. 787-801.
@article{64238bba5c36456795614d49dda8c410,
title = "Developing Drugs for Core Social and Communication Impairment in Autism",
abstract = "There are many challenges to studying drug effects on core social and language impairment in autism. Drugs such as fenfluramine, naltrexone, and secretin do not appear to be efficacious for these core symptoms. Risperidone has led to improvement in some aspects of social relatedness when used to treat irritability in autism. More research is needed on the utility of selective serotonin reuptake inhibitors, cholinergic drugs, glutamatergic drugs, and oxytocin for core autistic symptoms.",
author = "Posey, {David J.} and Erickson, {Craig A.} and McDougle, {Christopher J.}",
year = "2008",
month = "10",
day = "1",
doi = "10.1016/j.chc.2008.06.010",
language = "English (US)",
volume = "17",
pages = "787--801",
journal = "Child and Adolescent Psychiatric Clinics of North America",
issn = "1056-4993",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Developing Drugs for Core Social and Communication Impairment in Autism

AU - Posey, David J.

AU - Erickson, Craig A.

AU - McDougle, Christopher J.

PY - 2008/10/1

Y1 - 2008/10/1

N2 - There are many challenges to studying drug effects on core social and language impairment in autism. Drugs such as fenfluramine, naltrexone, and secretin do not appear to be efficacious for these core symptoms. Risperidone has led to improvement in some aspects of social relatedness when used to treat irritability in autism. More research is needed on the utility of selective serotonin reuptake inhibitors, cholinergic drugs, glutamatergic drugs, and oxytocin for core autistic symptoms.

AB - There are many challenges to studying drug effects on core social and language impairment in autism. Drugs such as fenfluramine, naltrexone, and secretin do not appear to be efficacious for these core symptoms. Risperidone has led to improvement in some aspects of social relatedness when used to treat irritability in autism. More research is needed on the utility of selective serotonin reuptake inhibitors, cholinergic drugs, glutamatergic drugs, and oxytocin for core autistic symptoms.

UR - http://www.scopus.com/inward/record.url?scp=50449092541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50449092541&partnerID=8YFLogxK

U2 - 10.1016/j.chc.2008.06.010

DO - 10.1016/j.chc.2008.06.010

M3 - Review article

C2 - 18775370

AN - SCOPUS:50449092541

VL - 17

SP - 787

EP - 801

JO - Child and Adolescent Psychiatric Clinics of North America

JF - Child and Adolescent Psychiatric Clinics of North America

SN - 1056-4993

IS - 4

ER -